Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
- FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met
- Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up
- Results support progression into Phase 2, with FDA IND clearance granted in the US and CTA approved in Germany
Copenhagen, Denmark and Boston, Massachusetts, 16 April 2026: Freya Biosciences (“Freya” or “the Company”), a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces positive topline results from its Phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain Lactobacillus consortium developed using Freya’s Dyscover™ platform which enables in human discovery, as a potential treatment for IVF-related embryo implantation failure.
